share_log

GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Delivers Shareholders Respectable 11% CAGR Over 3 Years, Surging 7.0% in the Last Week Alone

GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Delivers Shareholders Respectable 11% CAGR Over 3 Years, Surging 7.0% in the Last Week Alone

光裕源中草藥(上海證券交易所代碼:600771)在3年內爲股東帶來了可觀的11%的複合年增長率,僅在上週就飆升了7.0%
Simply Wall St ·  02/08 06:21

It hasn't been the best quarter for GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHSE:600771) shareholders, since the share price has fallen 13% in that time. But over three years, the returns would have left most investors smiling In fact, the company's share price bested the return of its market index in that time, posting a gain of 38%.

對於廣裕源中藥材有限公司(SHSE: 600771)股東來說,這並不是最好的季度,因爲當時股價已經下跌了13%。但是在三年內,回報會讓大多數投資者微笑。實際上,該公司的股價超過了當時的市場指數回報率,漲幅爲38%。

Since it's been a strong week for GuangYuYuan Chinese Herbal Medicine shareholders, let's have a look at trend of the longer term fundamentals.

由於對光裕源中藥股東來說,這是強勁的一週,讓我們來看看長期基本面的走勢。

Given that GuangYuYuan Chinese Herbal Medicine didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

鑑於光裕源中草藥在過去十二個月中沒有盈利,我們將專注於收入增長,以快速了解其業務發展。當一家公司沒有盈利時,我們通常預計收入會有良好的增長。這是因爲快速的收入增長可以很容易地推斷出來預測利潤,通常規模相當大。

In the last 3 years GuangYuYuan Chinese Herbal Medicine saw its revenue grow at 2.1% per year. That's not a very high growth rate considering it doesn't make profits. The modest growth is probably broadly reflected in the share price, which is up 11%, per year over 3 years. The real question is when the business will generate profits, and how quickly they will grow. Given the market doesn't seem too excited about the stock, a closer look at the financial data could pay off, if you can find indications of a stronger growth trend in the future.

在過去的3年中,光裕源中藥的收入以每年2.1%的速度增長。考慮到它沒有盈利,這不是一個很高的增長率。這種溫和的增長可能廣泛反映在股價上,股價在3年內每年上漲11%。真正的問題是企業何時會產生利潤,以及它們將以多快的速度增長。鑑於市場似乎對該股並不太興奮,如果你能發現未來增長趨勢更強勁的跡象,仔細研究財務數據可能會得到回報。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到收入和收入隨時間推移而發生的變化(點擊圖表查看確切值)。

earnings-and-revenue-growth
SHSE:600771 Earnings and Revenue Growth February 7th 2024
SHSE: 600771 2024 年 2 月 7 日收益和收入增長

If you are thinking of buying or selling GuangYuYuan Chinese Herbal Medicine stock, you should check out this FREE detailed report on its balance sheet.

如果您正在考慮買入或賣出光裕源中草藥股票,則應在其資產負債表上查看這份免費的詳細報告。

A Different Perspective

不同的視角

While the broader market lost about 24% in the twelve months, GuangYuYuan Chinese Herbal Medicine shareholders did even worse, losing 29%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - GuangYuYuan Chinese Herbal Medicine has 1 warning sign we think you should be aware of.

儘管整個市場在十二個月中下跌了約24%,但光裕源中藥股東的表現甚至更糟,跌幅爲29%。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。好的一面是,長期股東賺了錢,在過去的五年中,每年增長6%。最近的拋售可能是一個機會,因此可能值得查看基本面數據以尋找長期增長趨勢的跡象。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,冒險吧——光裕源中草藥有 1 個我們認爲你應該注意的警告信號。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想與管理層一起購買股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論